For the quarter ending 2025-09-30, MXCT had -$2,252K decrease in cash & cash equivalents over the period. -$7,758K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -12,416 | -22,618 |
| Depreciation and amortization | 1,072 | 2,196 |
| Lease right-of-use asset amortization | 209 | 378 |
| Net book value of consigned equipment sold | 15 | 55 |
| Loss on disposal of property and equipment | -19 | -113 |
| Stock-based compensation | 1,954 | 6,553 |
| Credit loss expense (recovery) | 19 | 10 |
| Change in excess/obsolete inventory reserve | 360 | 165 |
| Amortization of discounts on investments | 584 | 1,635 |
| Accounts receivable | 2,572 | 1,077 |
| Inventory | 107 | -754 |
| Prepaid expense and other current assets | 29 | -773 |
| Other assets | -216 | 1,140 |
| Accounts payable, accrued expenses and other | 2,002 | -5,340 |
| Operating lease liability | -346 | -593 |
| Deferred revenue | 2,751 | -2,831 |
| Other liabilities | -21 | -26 |
| Net cash used in operating activities | -7,458 | -24,263 |
| Purchases of investments | 34,508 | 63,523 |
| Maturities of investments | 40,000 | 77,600 |
| Purchases of property and equipment | 300 | 1,237 |
| Acquisition of business, net of cash acquired of 541 | 0 | 1,773 |
| Net cash provided by investing activities | 5,192 | 11,067 |
| Proceeds from exercise of stock options | 14 | 403 |
| Proceeds from issuance of common stock under employee stock purchase plan | 0 | 134 |
| Net cash provided by financing activities | 14 | 537 |
| Net decrease in cash and cash equivalents | -2,252 | -12,659 |
| Cash and cash equivalents at beginning of period | 27,884 | - |
| Cash and cash equivalents at end of period | 12,973 | - |
MAXCYTE, INC. (MXCT)
MAXCYTE, INC. (MXCT)